A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Venglustat (Primary) ; Imiglucerase
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms LEAP
- Sponsors Sanofi Genzyme
- 02 Jan 2017 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.
- 02 Jan 2017 Planned primary completion date changed from 1 Sep 2022 to 1 Oct 2022.
- 06 Dec 2016 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.